v3.26.3
Related Party Transactions
9 Months Ended
Sep. 30, 2026
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 18 - RELATED PARTY TRANSACTIONS:

 

a. Chief Scientific Officer

 

On July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY Ltd. (“KNRY”), an Israeli company owned by the Company’s Chief Scientific Officer, whereby the Chief Scientific Officer, through KNRY, provides services to the Company (the “Consulting Agreement”). The Consulting Agreement is terminable by either party upon 140 days prior written notice. The Consulting Agreement, as amended, provides that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreement. 

 

Effective as of July 1, 2024, the monthly consulting fee of the Chief Scientific Officer is NIS 134,550 ($37).

 

On April 1, 2025, the Company entered into a new consulting agreement with KNRY, whereby the Chief Scientific Officer, through KNRY, provides services as Chief Scientific Officer of the Company. The agreement is terminable by either party upon 140 days prior written notice. The agreement provides that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the agreement. Under the agreement, the initial monthly consulting fee of the Chief Scientific Officer was NIS 67,275 ($18). Pursuant to the agreement, KNRY and the Chief Scientific Officer each agreed that during the term of the agreement and for a 12-month period thereafter, neither of them will compete with the Company nor solicit employees of the Company.

 

Effective as of January 1, 2026 and September 1, 2026, the monthly consulting fee of the Chief Scientific Officer was increased to NIS 71,648 ($22) and NIS 82,395 ($27), respectively.

 

On April 1, 2025, the Company, through the Subsidiary, also entered into an employment agreement with the Chief Scientific Officer, pursuant to which the initial gross monthly salary of the Chief Scientific Officer was NIS 51,750 ($14) in consideration for her services as Chief Scientific Officer of the Subsidiary. The Chief Scientific Officer is also provided with a phone and a company car pursuant to the terms of her agreement.

 

Effective as of January 1, 2026 and September 1, 2026, the gross monthly salary of the Chief Scientific Officer was increased to NIS 55,114 ($17) and NIS 63,381 ($21), respectively.

 

b. President and Chief Executive Officer

 

On July 1, 2024, the Company entered into a consulting agreement with Shnida Ltd. (“Shnida”), whereby the Company’s President and Chief Executive Officer, through Shnida, provides services as President and Chief Executive Officer of the Company. The agreement is terminable by either party upon 140 days prior written notice. The agreement provides that Shnida will be reimbursed for reasonable expenses incurred in connection with performance of the agreement. Under the agreement, the initial monthly consulting fee of the President and Chief Executive Officer was NIS 111,349 ($31). Pursuant to the agreement, Shnida and the President and Chief Executive Officer each agreed that during the term of the agreement and for a 12-month period thereafter, neither of them will compete with the Company nor solicit employees of the Company.

 

Effective as of January 1, 2026 and September 1, 2026, the monthly consulting fee of the President and Chief Executive Officer was increased to NIS 118,587 ($37) and NIS 149,169 ($50), respectively.

 

In addition, the Company, through the Subsidiary, has entered into an employment agreement with the President and Chief Executive Officer, effective as of July 1, 2024, pursuant to which, effective as of January 1, 2024, the President and Chief Executive Officer receives a gross monthly salary of NIS 59,330 ($16) in consideration for his services as President and Chief Executive Officer of the Subsidiary. In addition, the President and Chief Executive Officer is provided with a phone and a company car pursuant to the terms of his agreement.

 

Effective as of January 1, 2026, the gross monthly salary of the President and Chief Executive Officer was increased to NIS 63,186 ($20).


c. Alpha Tau

 

The Company holds an investment in Alpha Tau that grants it significant influence over the investee and, accordingly, Alpha Tau is a related party of the Company. For details regarding the Services Agreement with Alpha Tau and the income recognized thereunder, see Note 2e1.

 

d. OraTech

 

Following the closing of the Lifeward transaction, OraTech is a subsidiary of Lifeward, in which the Company holds an investment (see Note 8) and, accordingly, OraTech is a related party of the Company. For details regarding the Clinical Trial Management Agreement with OraTech and the amounts charged and recognized thereunder, see Note 2e3.

 

e. Lifeward

 

The Company holds an investment in Lifeward that grants it significant influence over the investee (see Notes 2g1 and 8b) and, accordingly, Lifeward is a related party of the Company. For details regarding the Lifeward Revenue Share and the balance recognized thereunder, see Note 8b3.